{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:58:16Z","timestamp":1791043096416,"version":"4.1.0"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R21AG055949"],"award-info":[{"award-number":["R21AG055949"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuromol Med"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s12017-019-08524-y","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T07:58:43Z","timestamp":1547711923000},"page":"12-24","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["The Promises and Challenges of Erythropoietin for Treatment of Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"21","author":[{"given":"Jiahong","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Michelle","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Vanderpoel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7459-0723","authenticated-orcid":false,"given":"Rachita K.","family":"Sumbria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"issue":"3","key":"8524_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2018.02.001","volume":"14","author":"Alzheimer\u2019s Association","year":"2018","unstructured":"Alzheimer's Association. (2018). Alzheimer\u2019s disease facts and figures (2018). Alzheimer\u2019s & Dementia, 14(3), 367\u2013429. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.001 .","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"8524_CR2","doi-asserted-by":"publisher","DOI":"10.4103\/2277-9175.100157","author":"Z Arabpoor","year":"2012","unstructured":"Arabpoor, Z., Hamidi, G., Rashidi, B., Shabrang, M., Alaei, H., Sharifi, M. R., et al. (2012). Erythropoietin improves neuronal proliferation in dentate gyrus of hippocampal formation in an animal model of Alzheimer\u2019s disease. Advanced Biomedical Research. https:\/\/doi.org\/10.4103\/2277-9175.100157 .","journal-title":"Advanced Biomedical Research"},{"issue":"12","key":"8524_CR3","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40263-017-0483-3","volume":"31","author":"A Ardura-Fabregat","year":"2017","unstructured":"Ardura-Fabregat, A., Boddeke, E., Boza-Serrano, A., Brioschi, S., Castro-Gomez, S., Ceyzeriat, K., et al. (2017). Targeting neuroinflammation to treat Alzheimer\u2019s disease. CNS Drugs, 31(12), 1057\u20131082. https:\/\/doi.org\/10.1007\/s40263-017-0483-3 .","journal-title":"CNS Drugs"},{"issue":"2","key":"8524_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3233\/JAD-141389","volume":"45","author":"M Armand-Ugon","year":"2015","unstructured":"Armand-Ugon, M., Aso, E., Moreno, J., Riera-Codina, M., Sanchez, A., Vegas, E., et al. (2015). Memory improvement in the AbetaPP\/PS1 mouse model of familial Alzheimer\u2019s disease induced by carbamylated-erythropoietin is accompanied by modulation of synaptic genes. Journal of Alzheimers Disease, 45(2), 407\u2013421. https:\/\/doi.org\/10.3233\/jad-150002 .","journal-title":"Journal of Alzheimers Disease"},{"issue":"5","key":"8524_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/nen.0b013e3180517b28","volume":"66","author":"MI Assaraf","year":"2007","unstructured":"Assaraf, M. I., Diaz, Z., Liberman, A., Miller, W. H. Jr., Arvanitakis, Z., Li, Y., et al. (2007). Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment. Journal of Neuropathology & Experimental Neurology, 66(5), 389\u2013398. https:\/\/doi.org\/10.1097\/nen.0b013e3180517b28 .","journal-title":"Journal of Neuropathology & Experimental Neurology"},{"issue":"5","key":"8524_CR6","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/med.21434","volume":"37","author":"SO Bachurin","year":"2017","unstructured":"Bachurin, S. O., Bovina, E. V., & Ustyugov, A. A. (2017). Drugs in clinical trials for Alzheimer\u2019s Disease: The major trends. Medicinal Research Reviews, 37(5), 1186\u20131225. https:\/\/doi.org\/10.1002\/med.21434 .","journal-title":"Medicinal Research Reviews"},{"issue":"1\u20133","key":"8524_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejphar.2004.10.035","volume":"505","author":"WA Banks","year":"2004","unstructured":"Banks, W. A., Jumbe, N. L., Farrell, C. L., Niehoff, M. L., & Heatherington, A. C. (2004). Passage of erythropoietic agents across the blood-brain barrier: A comparison of human and murine erythropoietin and the analog darbepoetin alfa. European Journal of Pharmacology, 505(1\u20133), 93\u2013101. https:\/\/doi.org\/10.1016\/j.ejphar.2004.10.035 .","journal-title":"European Journal of Pharmacology"},{"issue":"4","key":"8524_CR8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1212\/01.WNL.0000151959.64379.1B","volume":"64","author":"AM Barrett","year":"2005","unstructured":"Barrett, A. M., Eslinger, P. J., Ballentine, N. H., & Heilman, K. M. (2005). Unawareness of cognitive deficit (cognitive anosognosia) in probable AD and control subjects. Neurology, 64(4), 693\u2013699. https:\/\/doi.org\/10.1212\/01.wnl.0000151959.64379.1b .","journal-title":"Neurology"},{"issue":"4558","key":"8524_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1126\/science.7046051","volume":"217","author":"RT Bartus","year":"1982","unstructured":"Bartus, R. T., Dean, R. L. 3rd, Beer, B., & Lippa, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science, 217(4558), 408\u2013414.","journal-title":"Science"},{"issue":"2","key":"8524_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20131660","volume":"211","author":"N Bien-Ly","year":"2014","unstructured":"Bien-Ly, N., Yu, Y. J., Bumbaca, D., Elstrott, J., Boswell, C. A., Zhang, Y., et al. (2014). Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. Journal of Experimental Medicine, 211(2), 233\u2013244. https:\/\/doi.org\/10.1084\/jem.20131660 .","journal-title":"Journal of Experimental Medicine"},{"issue":"3","key":"8524_CR11","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1124\/jpet.109.165092","volume":"333","author":"RJ Boado","year":"2010","unstructured":"Boado, R. J., Hui, E. K., Lu, J. Z., & Pardridge, W. M. (2010). Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. Journal of Pharmacology and Experimental Therapeutics, 333(3), 961\u2013969. https:\/\/doi.org\/10.1124\/jpet.109.165092 .","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"4","key":"8524_CR12","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/bit.22135","volume":"102","author":"RJ Boado","year":"2009","unstructured":"Boado, R. J., Zhang, Y., Wang, Y., & Pardridge, W. M. (2009). Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnology and Bioengineering, 102(4), 1251\u20131258. https:\/\/doi.org\/10.1002\/bit.22135 .","journal-title":"Biotechnology and Bioengineering"},{"issue":"4","key":"8524_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","volume":"112","author":"H Braak","year":"2006","unstructured":"Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006). Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathology, 112(4), 389\u2013404. https:\/\/doi.org\/10.1007\/s00401-006-0127-z .","journal-title":"Acta Neuropathology"},{"issue":"3","key":"8524_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.neulet.2006.06.011","volume":"404","author":"J Brettschneider","year":"2006","unstructured":"Brettschneider, J., Widl, K., Ehrenreich, H., Riepe, M., & Tumani, H. (2006). Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases. Neuroscience Letters, 404(3), 347\u2013351. https:\/\/doi.org\/10.1016\/j.neulet.2006.06.011 .","journal-title":"Neuroscience Letters"},{"issue":"19","key":"8524_CR15","doi-asserted-by":"publisher","first-page":"10526","DOI":"10.1073\/pnas.97.19.10526","volume":"97","author":"ML Brines","year":"2000","unstructured":"Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N. C., Cerami, C., et al. (2000). Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proceedings of the National Academy of Sciences of the United States of America, 97(19), 10526\u201310531.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"8524_CR16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1471-4159.2005.03099.x","volume":"93","author":"AL Brunkan","year":"2005","unstructured":"Brunkan, A. L., & Goate, A. M. (2005). Presenilin function and gamma-secretase activity. Journal of Neurochemistry, 93(4), 769\u2013792. https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03099.x .","journal-title":"Journal of Neurochemistry"},{"issue":"89","key":"8524_CR17","doi-asserted-by":"publisher","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","volume":"3","author":"JM Castellano","year":"2011","unstructured":"Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., et al. (2011). Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Science Translational Medicine, 3(89), 89ra57. https:\/\/doi.org\/10.1126\/scitranslmed.3002156 .","journal-title":"Science Translational Medicine"},{"key":"8524_CR18","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00594","author":"R Chang","year":"2018","unstructured":"Chang, R., Maghribi, A., Vanderpoel, A., Vasilevko, V., Cribbs, V., Boado, D. H., R., et al (2018). Brain penetrating bifunctional erythropoietin-transferrin receptor antibody fusion protein for Alzheimer\u2019s disease. Molecular Pharmaceutics. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00594 .","journal-title":"Molecular Pharmaceutics"},{"issue":"1","key":"8524_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12017-009-8104-z","volume":"12","author":"VW Chow","year":"2010","unstructured":"Chow, V. W., Mattson, M. P., Wong, P. C., & Gleichmann, M. (2010). An overview of APP processing enzymes and products. Neuromolecular Medicine, 12(1), 1\u201312. https:\/\/doi.org\/10.1007\/s12017-009-8104-z .","journal-title":"Neuromolecular Medicine"},{"issue":"Pt 10","key":"8524_CR20","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1093\/brain\/awu213","volume":"137","author":"L Collin","year":"2014","unstructured":"Collin, L., Bohrmann, B., Gopfert, U., Oroszlan-Szovik, K., Ozmen, L., & Gruninger, F. (2014). Neuronal uptake of tau\/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer\u2019s disease. Brain, 137(Pt 10), 2834\u20132846. https:\/\/doi.org\/10.1093\/brain\/awu213 .","journal-title":"Brain"},{"issue":"1","key":"8524_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1602\/neurorx.2.1.27","volume":"2","author":"EM Cornford","year":"2005","unstructured":"Cornford, E. M., & Hyman, S. (2005). Localization of brain endothelial luminal and abluminal transporters with immunogold electron microscopy. NeuroRx, 2(1), 27\u201343. https:\/\/doi.org\/10.1602\/neurorx.2.1.27 .","journal-title":"NeuroRx"},{"issue":"183","key":"8524_CR22","doi-asserted-by":"publisher","first-page":"183ra157","DOI":"10.1126\/scitranslmed.3005338","volume":"5","author":"JA Couch","year":"2013","unstructured":"Couch, J. A., Yu, Y. J., Zhang, Y., Tarrant, J. M., Fuji, R. N., Meilandt, W. J., et al. (2013). Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Science Translational Medicine, 5(183), 183ra157. https:\/\/doi.org\/10.1126\/scitranslmed.3005338 . 181 \u2013 112.","journal-title":"Science Translational Medicine"},{"issue":"2\u20133","key":"8524_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF03033787","volume":"2","author":"W Danysz","year":"2000","unstructured":"Danysz, W., Parsons, C. G., Mobius, H. J., Stoffler, A., & Quack, G. (2000). Neuroprotective and symptomatological action of memantine relevant for Alzheimer\u2019s disease\u2014A unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Research, 2(2\u20133), 85\u201397.","journal-title":"Neurotoxicity Research"},{"issue":"3","key":"8524_CR24","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3233\/JAD-142337","volume":"44","author":"V Dauphinot","year":"2015","unstructured":"Dauphinot, V., Delphin-Combe, F., Mouchoux, C., Dorey, A., Bathsavanis, A., Makaroff, Z., et al. (2015). Risk factors of caregiver burden among patients with Alzheimer\u2019s disease or related disorders: A cross-sectional study. Journal of Alzheimers Disease, 44(3), 907\u2013916. https:\/\/doi.org\/10.3233\/jad-142337 .","journal-title":"Journal of Alzheimers Disease"},{"issue":"8","key":"8524_CR25","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1073\/pnas.80.8.2258","volume":"80","author":"A Dautry-Varsat","year":"1983","unstructured":"Dautry-Varsat, A., Ciechanover, A., & Lodish, H. F. (1983). pH and the recycling of transferrin during receptor-mediated endocytosis. Proceedings of the National Academy of Sciences of the United States of America, 80(8), 2258\u20132262.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"8524_CR26","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.neurobiolaging.2007.02.029","volume":"29","author":"FG De Felice","year":"2008","unstructured":"De Felice, F. G., Wu, D., Lambert, M. P., Fernandez, S. J., Velasco, P. T., Lacor, P. N., et al. (2008). Alzheimer\u2019s disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiology of Aging, 29(9), 1334\u20131347. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2007.02.029 .","journal-title":"Neurobiology of Aging"},{"issue":"5","key":"8524_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky, S. T., & Scheff, S. W. (1990). Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: Correlation with cognitive severity. Annals of Neurology, 27(5), 457\u2013464. https:\/\/doi.org\/10.1002\/ana.410270502 .","journal-title":"Annals of Neurology"},{"issue":"2","key":"8524_CR28","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1471-4159.2005.03038.x","volume":"93","author":"Z Diaz","year":"2005","unstructured":"Diaz, Z., Assaraf, M. I., Miller, W. H. Jr., & Schipper, H. M. (2005). Astroglial cytoprotection by erythropoietin pre-conditioning: Implications for ischemic and degenerative CNS disorders. Journal of Neurochemistry, 93(2), 392\u2013402. https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03038.x .","journal-title":"Journal of Neurochemistry"},{"issue":"9","key":"8524_CR29","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1073\/pnas.92.9.3717","volume":"92","author":"M Digicaylioglu","year":"1995","unstructured":"Digicaylioglu, M., Bichet, S., Marti, H. H., Wenger, R. H., Rivas, L. A., Bauer, C., et al. (1995). Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proceedings of the National Academy of Sciences of the United States of America, 92(9), 3717\u20133720.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"8524_CR30","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3389\/fphys.2012.00464","volume":"3","author":"MC Dinamarca","year":"2012","unstructured":"Dinamarca, M. C., Rios, J. A., & Inestrosa, N. C. (2012). Postsynaptic receptors for amyloid-beta oligomers as mediators of neuronal damage in Alzheimer\u2019s disease. Frontiers in Physiology, 3, 464. https:\/\/doi.org\/10.3389\/fphys.2012.00464 .","journal-title":"Frontiers in Physiology"},{"issue":"4","key":"8524_CR31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. (2013). A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. New England Journal of Medicine, 369(4), 341\u2013350. https:\/\/doi.org\/10.1056\/NEJMoa1210951 .","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"8524_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s12035-012-8271-z","volume":"46","author":"GP Eckert","year":"2012","unstructured":"Eckert, G. P., Renner, K., Eckert, S. H., Eckmann, J., Hagl, S., Abdel-Kader, R. M., et al. (2012). Mitochondrial dysfunction\u2014A pharmacological target in Alzheimer\u2019s disease. Molecular Neurobiology, 46(1), 136\u2013150. https:\/\/doi.org\/10.1007\/s12035-012-8271-z .","journal-title":"Molecular Neurobiology"},{"issue":"11","key":"8524_CR33","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00702-006-0575-6","volume":"113","author":"P Eikelenboom","year":"2006","unstructured":"Eikelenboom, P., Veerhuis, R., Scheper, W., Rozemuller, A. J., van Gool, W. A., & Hoozemans, J. J. (2006). The significance of neuroinflammation in understanding Alzheimer\u2019s disease. Journal of Neural Transmission (Vienna), 113(11), 1685\u20131695. https:\/\/doi.org\/10.1007\/s00702-006-0575-6 .","journal-title":"Journal of Neural Transmission (Vienna)"},{"issue":"11","key":"8524_CR34","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.1073\/pnas.1031753100","volume":"100","author":"S Erbayraktar","year":"2003","unstructured":"Erbayraktar, S., Grasso, G., Sfacteria, A., Xie, Q. W., Coleman, T., Kreilgaard, M., et al. (2003). Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proceedings of the National Academy of Sciences of the United States of America, 100(11), 6741\u20136746. https:\/\/doi.org\/10.1073\/pnas.1031753100 .","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"8524_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pbb.2014.12.011","volume":"130","author":"P Esmaeili Tazangi","year":"2015","unstructured":"Esmaeili Tazangi, P., Moosavi, S. M., Shabani, M., & Haghani, M. (2015). Erythropoietin improves synaptic plasticity and memory deficits by decrease of the neurotransmitter release probability in the rat model of Alzheimer\u2019s disease. Pharmacology Biochemistry and Behavior, 130, 15\u201321. https:\/\/doi.org\/10.1016\/j.pbb.2014.12.011 .","journal-title":"Pharmacology Biochemistry and Behavior"},{"issue":"Pt 12","key":"8524_CR36","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1093\/brain\/awv288","volume":"138","author":"Z Fan","year":"2015","unstructured":"Fan, Z., Okello, A. A., Brooks, D. J., & Edison, P. (2015). Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer\u2019s disease. Brain, 138(Pt 12), 3685\u20133698. https:\/\/doi.org\/10.1093\/brain\/awv288 .","journal-title":"Brain"},{"issue":"2","key":"8524_CR37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/jnr.490180206","volume":"18","author":"JB Fishman","year":"1987","unstructured":"Fishman, J. B., Rubin, J. B., Handrahan, J. V., Connor, J. R., & Fine, R. E. (1987). Receptor-mediated transcytosis of transferrin across the blood-brain barrier. Journal of Neuroscience Research, 18(2), 299\u2013304. https:\/\/doi.org\/10.1002\/jnr.490180206 .","journal-title":"Journal of Neuroscience Research"},{"issue":"5","key":"8524_CR38","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1001\/archneur.55.5.689","volume":"55","author":"P Giannakopoulos","year":"1998","unstructured":"Giannakopoulos, P., Duc, M., Gold, G., Hof, P. R., Michel, J. P., & Bouras, C. (1998). Pathologic correlates of apraxia in Alzheimer disease. Archives in Neurology, 55(5), 689\u2013695.","journal-title":"Archives in Neurology"},{"issue":"6359","key":"8524_CR39","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1126\/science.aao2825","volume":"358","author":"L Gremer","year":"2017","unstructured":"Gremer, L., Scholzel, D., Schenk, C., Reinartz, E., & Labahn, J. (2017). Fibril structure of amyloid-beta(1\u201342) by cryo-electron microscopy. Science, 358(6359), 116\u2013119, https:\/\/doi.org\/10.1126\/science.aao2825 .","journal-title":"Science"},{"issue":"1","key":"8524_CR40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.blre.2012.12.003","volume":"27","author":"VH Haase","year":"2013","unstructured":"Haase, V. H. (2013). Regulation of erythropoiesis by hypoxia-inducible factors. Blood Review, 27(1), 41\u201353. https:\/\/doi.org\/10.1016\/j.blre.2012.12.003 .","journal-title":"Blood Review"},{"issue":"5441","key":"8524_CR41","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1126\/science.286.5441.916","volume":"286","author":"C Haass","year":"1999","unstructured":"Haass, C., & De Strooper, B. (1999). The presenilins in Alzheimer\u2019s disease\u2013proteolysis holds the key. Science, 286(5441), 916\u2013919.","journal-title":"Science"},{"issue":"4","key":"8524_CR42","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1111\/j.1471-4159.2009.06181.x","volume":"110","author":"J Hardy","year":"2009","unstructured":"Hardy, J. (2009). The amyloid hypothesis for Alzheimer\u2019s disease: A critical reappraisal. Journal of Neurochemistry, 110(4), 1129\u20131134. https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06181.x .","journal-title":"Journal of Neurochemistry"},{"issue":"5054","key":"8524_CR43","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy, J. A., & Higgins, G. A. (1992). Alzheimer\u2019s disease: The amyloid cascade hypothesis. Science, 256(5054), 184\u2013185.","journal-title":"Science"},{"issue":"4","key":"8524_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00002093-200110000-00002","volume":"15","author":"LE Hebert","year":"2001","unstructured":"Hebert, L. E., Beckett, L. A., Scherr, P. A., & Evans, D. A. (2001). Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Disease and Associated Disorders, 15(4), 169\u2013173.","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"4","key":"8524_CR45","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G., Brosseron, F., Feinstein, D. L., et al. (2015). Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurology, 14(4), 388\u2013405. https:\/\/doi.org\/10.1016\/s1474-4422(15)70016-5 .","journal-title":"Lancet Neurology"},{"issue":"6286","key":"8524_CR46","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., et al. (2016). Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science, 352(6286), 712\u2013716. https:\/\/doi.org\/10.1126\/science.aad8373 .","journal-title":"Science"},{"key":"8524_CR47","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.neuroscience.2018.08.001","volume":"388","author":"E Hooshmandi","year":"2018","unstructured":"Hooshmandi, E., Motamedi, F., Moosavi, M., Katinger, H., Zakeri, Z., Zaringhalam, J., et al. (2018). CEPO-Fc (An EPO Derivative) protects hippocampus against abeta-induced memory deterioration: a behavioral and molecular study in a rat model of abeta toxicity. Neuroscience, 388, 405\u2013417. https:\/\/doi.org\/10.1016\/j.neuroscience.2018.08.001 .","journal-title":"Neuroscience"},{"issue":"2","key":"8524_CR48","doi-asserted-by":"publisher","first-page":"308","DOI":"10.7150\/thno.17155","volume":"7","author":"G Hultqvist","year":"2017","unstructured":"Hultqvist, G., Syvanen, S., Fang, X. T., Lannfelt, L., & Sehlin, D. (2017). Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor. Theranostics, 7(2), 308\u2013318. https:\/\/doi.org\/10.7150\/thno.17155 .","journal-title":"Theranostics"},{"issue":"2","key":"8524_CR49","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1046\/j.1471-4159.1998.70020883.x","volume":"70","author":"J Huwyler","year":"1998","unstructured":"Huwyler, J., & Pardridge, W. M. (1998). Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. Journal of Neurochemistry, 70(2), 883\u2013886.","journal-title":"Journal of Neurochemistry"},{"issue":"12","key":"8524_CR50","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1212\/WNL.0000000000000240","volume":"82","author":"BD James","year":"2014","unstructured":"James, B. D., Leurgans, S. E., Hebert, L. E., Scherr, P. A., Yaffe, K., & Bennett, D. A. (2014). Contribution of Alzheimer disease to mortality in the United States. Neurology, 82(12), 1045\u20131050. https:\/\/doi.org\/10.1212\/wnl.0000000000000240 .","journal-title":"Neurology"},{"issue":"5990","key":"8524_CR51","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/312162a0","volume":"312","author":"WA Jefferies","year":"1984","unstructured":"Jefferies, W. A., Brandon, M. R., Hunt, S. V., Williams, A. F., Gatter, K. C., & Mason, D. Y. (1984). Transferrin receptor on endothelium of brain capillaries. Nature, 312(5990), 162\u2013163.","journal-title":"Nature"},{"issue":"1","key":"8524_CR52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/1389201053167257","volume":"6","author":"W Jelkmann","year":"2005","unstructured":"Jelkmann, W. (2005). Effects of erythropoietin on brain function. Current Pharmaceutical Biotechnology, 6(1), 65\u201379.","journal-title":"Current Pharmaceutical Biotechnology"},{"issue":"5","key":"8524_CR53","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000356193","volume":"40","author":"W Jelkmann","year":"2013","unstructured":"Jelkmann, W. (2013). Physiology and pharmacology of erythropoietin. Transfusion Medicine and Hemotherapy, 40(5), 302\u2013309. https:\/\/doi.org\/10.1159\/000356193 .","journal-title":"Transfusion Medicine and Hemotherapy"},{"issue":"21","key":"8524_CR54","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1182\/blood-2016-10-743880","volume":"128","author":"P Ji","year":"2016","unstructured":"Ji, P. (2016). Pericytes: new EPO-producing cells in the brain. Blood, 128(21), 2483\u20132485. https:\/\/doi.org\/10.1182\/blood-2016-10-743880 .","journal-title":"Blood"},{"issue":"10","key":"8524_CR55","doi-asserted-by":"publisher","first-page":"e907","DOI":"10.1038\/tp.2016.186","volume":"6","author":"SS Jiao","year":"2016","unstructured":"Jiao, S. S., Shen, L. L., Zhu, C., Bu, X. L., Liu, Y. H., Liu, C. H., et al. (2016). Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer\u2019s disease. Translational Psychiatry, 6(10), e907. https:\/\/doi.org\/10.1038\/tp.2016.186 .","journal-title":"Translational Psychiatry"},{"issue":"9","key":"8524_CR56","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s11095-007-9379-0","volume":"24","author":"AR Jones","year":"2007","unstructured":"Jones, A. R., & Shusta, E. V. (2007). Blood-brain barrier transport of therapeutics via receptor-mediation. Pharmaceutical Research, 24(9), 1759\u20131771. https:\/\/doi.org\/10.1007\/s11095-007-9379-0 .","journal-title":"Pharmaceutical Research"},{"issue":"1","key":"8524_CR57","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1203\/00006450-199801000-00007","volume":"43","author":"SE Juul","year":"1998","unstructured":"Juul, S. E., Anderson, D. K., Li, Y., & Christensen, R. D. (1998). Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatrics Research, 43(1), 40\u201349. https:\/\/doi.org\/10.1203\/00006450-199804001-00243 .","journal-title":"Pediatrics Research"},{"issue":"4","key":"8524_CR58","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3233\/JAD-161118","volume":"57","author":"R Kandimalla","year":"2017","unstructured":"Kandimalla, R., & Reddy, P. H. (2017). Therapeutics of neurotransmitters in Alzheimer\u2019s disease. Journal of Alzheimers Diseases, 57(4), 1049\u20131069. https:\/\/doi.org\/10.3233\/jad-161118 .","journal-title":"Journal of Alzheimers Diseases"},{"issue":"1","key":"8524_CR59","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","volume":"77","author":"CM Karch","year":"2015","unstructured":"Karch, C. M., & Goate, A. M. (2015). Alzheimer\u2019s disease risk genes and mechanisms of disease pathogenesis. Biological Psychiatry, 77(1), 43\u201351. https:\/\/doi.org\/10.1016\/j.biopsych.2014.05.006 .","journal-title":"Biological Psychiatry"},{"issue":"2","key":"8524_CR60","first-page":"126","volume":"26","author":"M Kato","year":"1998","unstructured":"Kato, M., Miura, K., Kamiyama, H., Okazaki, A., Kumaki, K., Kato, Y., et al. (1998). Pharmacokinetics of erythropoietin in genetically anemic mice. Drug Metabolism and Disposition, 26(2), 126\u2013131.","journal-title":"Drug Metabolism and Disposition"},{"issue":"1","key":"8524_CR61","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1460-9568.2007.05635.x","volume":"26","author":"VR King","year":"2007","unstructured":"King, V. R., Averill, S. A., Hewazy, D., Priestley, J. V., Torup, L., & Michael-Titus, A. T. (2007). Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. European Journal of Neuroscience, 26(1), 90\u2013100. https:\/\/doi.org\/10.1111\/j.1460-9568.2007.05635.x .","journal-title":"European Journal of Neuroscience"},{"issue":"1\u20132","key":"8524_CR62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0006-8993(93)90850-M","volume":"609","author":"Y Konishi","year":"1993","unstructured":"Konishi, Y., Chui, D. H., Hirose, H., Kunishita, T., & Tabira, T. (1993). Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Research, 609(1\u20132), 29\u201335.","journal-title":"Brain Research"},{"issue":"7","key":"8524_CR63","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.2174\/138920112800624364","volume":"13","author":"EE Konofagou","year":"2012","unstructured":"Konofagou, E. E., Tung, Y. S., Choi, J., Deffieux, T., Baseri, B., & Vlachos, F. (2012). Ultrasound-induced blood-brain barrier opening. Current Pharmaceutical Biotechnology, 13(7), 1332\u20131345.","journal-title":"Current Pharmaceutical Biotechnology"},{"issue":"10","key":"8524_CR64","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1517\/13543784.2010.517954","volume":"19","author":"PA Lapchak","year":"2010","unstructured":"Lapchak, P. A. (2010). Erythropoietin molecules to treat acute ischemic stroke: A translational dilemma! Expert Opinion on Investigational Drugs, 19(10), 1179\u20131186. https:\/\/doi.org\/10.1517\/13543784.2010.517954 .","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"3","key":"8524_CR65","first-page":"1048","volume":"292","author":"HJ Lee","year":"2000","unstructured":"Lee, H. J., Engelhardt, B., Lesley, J., Bickel, U., & Pardridge, W. M. (2000). Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. Journal of Pharmacology and Experimental Therapeutics, 292(3), 1048\u20131052.","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"8524_CR66","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1471-4159.2011.07534.x","volume":"120","author":"ST Lee","year":"2012","unstructured":"Lee, S. T., Chu, K., Park, J. E., Jung, K. H., Jeon, D., Lim, J. Y., et al. (2012). Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-beta burden in Alzheimer\u2019s disease models. Journal of Neurochemistry, 120(1), 115\u2013124. https:\/\/doi.org\/10.1111\/j.1471-4159.2011.07534.x .","journal-title":"Journal of Neurochemistry"},{"issue":"1","key":"8524_CR67","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s12035-012-8307-4","volume":"46","author":"K Leuner","year":"2012","unstructured":"Leuner, K., Muller, W. E., & Reichert, A. S. (2012). From mitochondrial dysfunction to amyloid beta formation: Novel insights into the pathogenesis of Alzheimer\u2019s disease. Molecular Neurobiology, 46(1), 186\u2013193. https:\/\/doi.org\/10.1007\/s12035-012-8307-4 .","journal-title":"Molecular Neurobiology"},{"issue":"2","key":"8524_CR68","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neulet.2008.07.007","volume":"442","author":"G Li","year":"2008","unstructured":"Li, G., Ma, R., Huang, C., Tang, Q., Fu, Q., Liu, H., et al. (2008). Protective effect of erythropoietin on beta-amyloid-induced PC12 cell death through antioxidant mechanisms. Neuroscience Letters, 442(2), 143\u2013147. https:\/\/doi.org\/10.1016\/j.neulet.2008.07.007 .","journal-title":"Neuroscience Letters"},{"issue":"1","key":"8524_CR69","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/00004647-200101000-00008","volume":"21","author":"JY Li","year":"2001","unstructured":"Li, J. Y., Boado, R. J., & Pardridge, W. M. (2001). Blood-brain barrier genomics. Journal of Cerebral Blood Flow & Metabolism, 21(1), 61\u201368. https:\/\/doi.org\/10.1097\/00004647-200101000-00008 .","journal-title":"Journal of Cerebral Blood Flow & Metabolism"},{"key":"8524_CR70","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.brainres.2015.05.031","volume":"1618","author":"YP Li","year":"2015","unstructured":"Li, Y. P., Yang, G. J., Jin, L., Yang, H. M., Chen, J., Chai, G. S., et al. (2015). Erythropoietin attenuates Alzheimer-like memory impairments and pathological changes induced by amyloid beta42 in mice. Brain Research, 1618, 159\u2013167. https:\/\/doi.org\/10.1016\/j.brainres.2015.05.031 .","journal-title":"Brain Research"},{"issue":"7","key":"8524_CR71","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","volume":"64","author":"JJ Lochhead","year":"2012","unstructured":"Lochhead, J. J., & Thorne, R. G. (2012). Intranasal delivery of biologics to the central nervous system. Advanced Drug Delivery Reviews, 64(7), 614\u2013628. https:\/\/doi.org\/10.1016\/j.addr.2011.11.002 .","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"Pt B","key":"8524_CR72","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.neuropharm.2014.11.018","volume":"96","author":"S Lombardo","year":"2015","unstructured":"Lombardo, S., & Maskos, U. (2015). Role of the nicotinic acetylcholine receptor in Alzheimer\u2019s disease pathology and treatment. Neuropharmacology, 96(Pt B), 255\u2013262, https:\/\/doi.org\/10.1016\/j.neuropharm.2014.11.018 .","journal-title":"Neuropharmacology"},{"key":"8524_CR73","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2147\/IJN.S61288","volume":"9","author":"CT Lu","year":"2014","unstructured":"Lu, C. T., Zhao, Y. Z., Wong, H. L., Cai, J., Peng, L., & Tian, X. Q. (2014). Current approaches to enhance CNS delivery of drugs across the brain barriers. International Journal of Nanomedicine, 9, 2241\u20132257. https:\/\/doi.org\/10.2147\/ijn.s61288 .","journal-title":"International Journal of Nanomedicine"},{"issue":"Pt 1","key":"8524_CR74","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1113\/jphysiol.2006.122689","volume":"578","author":"C Lundby","year":"2007","unstructured":"Lundby, C., Thomsen, J. J., Boushel, R., Koskolou, M., Warberg, J., Calbet, J. A., et al. (2007). Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. Journal of Physiology, 578(Pt 1), 309\u2013314. https:\/\/doi.org\/10.1113\/jphysiol.2006.122689 .","journal-title":"Journal of Physiology"},{"issue":"6\u20137","key":"8524_CR75","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.neuropharm.2009.02.006","volume":"56","author":"R Ma","year":"2009","unstructured":"Ma, R., Xiong, N., Huang, C., Tang, Q., Hu, B., Xiang, J., et al. (2009). Erythropoietin protects PC12 cells from beta-amyloid(25\u201335)-induced apoptosis via PI3K\/Akt signaling pathway. Neuropharmacology, 56(6\u20137), 1027\u20131034. https:\/\/doi.org\/10.1016\/j.neuropharm.2009.02.006 .","journal-title":"Neuropharmacology"},{"issue":"4","key":"8524_CR76","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1460-9568.1996.tb01252.x","volume":"8","author":"HH Marti","year":"1996","unstructured":"Marti, H. H., Wenger, R. H., Rivas, L. A., Straumann, U., Digicaylioglu, M., Henn, V., et al. (1996). Erythropoietin gene expression in human, monkey and murine brain. European Journal of Neuroscience, 8(4), 666\u2013676.","journal-title":"European Journal of Neuroscience"},{"issue":"30","key":"8524_CR77","doi-asserted-by":"crossref","first-page":"19488","DOI":"10.1016\/S0021-9258(17)32195-6","volume":"269","author":"S Masuda","year":"1994","unstructured":"Masuda, S., Okano, M., Yamagishi, K., Nagao, M., Ueda, M., & Sasaki, R. (1994). A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. The Journal of Biological Chemistry, 269(30), 19488\u201319493.","journal-title":"The Journal of Biological Chemistry"},{"issue":"11","key":"8524_CR78","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1177\/0269881113494939","volume":"27","author":"T Maurice","year":"2013","unstructured":"Maurice, T., Mustafa, M. H., Desrumaux, C., Keller, E., Naert, G., de la Garc\u00eda-Barcel\u00f3, M. C., et al. (2013). Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Abeta(2)(5)(-)(3)(5) non-transgenic mouse model of Alzheimer\u2019s disease. Journal of Psychopharmacology, 27(11), 1044\u20131057. https:\/\/doi.org\/10.1177\/0269881113494939 .","journal-title":"Journal of Psychopharmacology"},{"key":"8524_CR79","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/epirev\/mxs007","volume":"35","author":"F Mawanda","year":"2013","unstructured":"Mawanda, F., & Wallace, R. (2013). Can infections cause Alzheimer\u2019s disease? Epidemiologic Reviews, 35, 161\u2013180. https:\/\/doi.org\/10.1093\/epirev\/mxs007 .","journal-title":"Epidemiologic Reviews"},{"issue":"5","key":"8524_CR80","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0278-5846(03)00124-6","volume":"27","author":"EG McGeer","year":"2003","unstructured":"McGeer, E. G., & McGeer, P. L. (2003). Inflammatory processes in Alzheimer\u2019s disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 27(5), 741\u2013749. https:\/\/doi.org\/10.1016\/s0278-5846(03)00124-6 .","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"6","key":"8524_CR81","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1371\/journal.pone.0000536","volume":"2","author":"S Melov","year":"2007","unstructured":"Melov, S., Adlard, P. A., Morten, K., Johnson, F., Golden, T. R., Hinerfeld, D., et al. (2007). Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS ONE, 2(6), e536. https:\/\/doi.org\/10.1371\/journal.pone.0000536 .","journal-title":"PLoS ONE"},{"issue":"7\u20138","key":"8524_CR82","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2119\/2006-00045.Mennini","volume":"12","author":"T Mennini","year":"2006","unstructured":"Mennini, T., De Paola, M., Bigini, P., Mastrotto, C., Fumagalli, E., Barbera, S., et al. (2006). Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Molecular Medicine, 12(7\u20138), 153\u2013160. https:\/\/doi.org\/10.2119\/2006-00045.Mennini .","journal-title":"Molecular Medicine"},{"issue":"16","key":"8524_CR83","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa0902234","volume":"361","author":"SL Mitchell","year":"2009","unstructured":"Mitchell, S. L., Teno, J. M., Kiely, D. K., Shaffer, M. L., Jones, R. N., Prigerson, H. G., et al. (2009). The clinical course of advanced dementia. New England Journal of Medicine, 361(16), 1529\u20131538. https:\/\/doi.org\/10.1056\/NEJMoa0902234 .","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"8524_CR84","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/j.1471-4159.2007.04976.x","volume":"103","author":"T Moos","year":"2007","unstructured":"Moos, T., Nielsen, T. R., Skjorringe, T., & Morgan, E. H. (2007). Iron trafficking inside the brain. Journal of Neurochemistry, 103(5), 1730\u20131740. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.04976.x .","journal-title":"Journal of Neurochemistry"},{"issue":"1","key":"8524_CR85","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0306-4522(96)00306-5","volume":"76","author":"E Morishita","year":"1997","unstructured":"Morishita, E., Masuda, S., Nagao, M., Yasuda, Y., & Sasaki, R. (1997). Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience, 76(1), 105\u2013116.","journal-title":"Neuroscience"},{"issue":"4","key":"8524_CR86","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/jnen\/60.4.386","volume":"60","author":"A Nagai","year":"2001","unstructured":"Nagai, A., Nakagawa, E., Choi, H. B., Hatori, K., Kobayashi, S., & Kim, S. U. (2001). Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. Journal of Neuropathology & Experimental Neurology, 60(4), 386\u2013392.","journal-title":"Journal of Neuropathology & Experimental Neurology"},{"issue":"933","key":"8524_CR87","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1136\/pmj.79.933.367","volume":"79","author":"T Ng","year":"2003","unstructured":"Ng, T., Marx, G., Littlewood, T., & Macdougall, I. (2003). Recombinant erythropoietin in clinical practice. Postgraduate Medical Journal, 79(933), 367\u2013376.","journal-title":"Postgraduate Medical Journal"},{"issue":"4","key":"8524_CR88","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nm840","volume":"9","author":"JA Nicoll","year":"2003","unstructured":"Nicoll, J. A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003). Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nature Medicine, 9(4), 448\u2013452. https:\/\/doi.org\/10.1038\/nm840 .","journal-title":"Nature Medicine"},{"issue":"1","key":"8524_CR89","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","volume":"81","author":"J Niewoehner","year":"2014","unstructured":"Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., et al. (2014). Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron, 81(1), 49\u201360. https:\/\/doi.org\/10.1016\/j.neuron.2013.10.061 .","journal-title":"Neuron"},{"issue":"2","key":"8524_CR90","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2217\/imt.11.170","volume":"4","author":"F Panza","year":"2012","unstructured":"Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., et al. (2012). Immunotherapy for Alzheimer\u2019s disease: From anti-beta-amyloid to tau-based immunization strategies. Immunotherapy, 4(2), 213\u2013238. https:\/\/doi.org\/10.2217\/imt.11.170 .","journal-title":"Immunotherapy"},{"issue":"2","key":"8524_CR91","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/YCO.0000000000000041","volume":"27","author":"F Panza","year":"2014","unstructured":"Panza, F., Logroscino, G., Imbimbo, B. P., & Solfrizzi, V. (2014). Is there still any hope for amyloid-based immunotherapy for Alzheimer\u2019s disease? Current Opinion in Psychiatry, 27(2), 128\u2013137. https:\/\/doi.org\/10.1097\/yco.0000000000000041 .","journal-title":"Current Opinion in Psychiatry"},{"issue":"1","key":"8524_CR92","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge, W. M. (2005). The blood-brain barrier: Bottleneck in brain drug development. NeuroRx, 2(1), 3\u201314. https:\/\/doi.org\/10.1602\/neurorx.2.1.3 .","journal-title":"NeuroRx"},{"issue":"34","key":"8524_CR93","first-page":"139","volume":"6","author":"WM Pardridge","year":"2006","unstructured":"Pardridge, W. M. (2006). Molecular Trojan horses for blood-brain barrier drug delivery. Discovery Medicine, 6(34), 139\u2013143.","journal-title":"Discovery Medicine"},{"issue":"5","key":"8524_CR94","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jalz.2009.06.003","volume":"5","author":"WM Pardridge","year":"2009","unstructured":"Pardridge, W. M. (2009). Alzheimer\u2019s disease drug development and the problem of the blood-brain barrier. Alzheimers Dementia, 5(5), 427\u2013432. https:\/\/doi.org\/10.1016\/j.jalz.2009.06.003 .","journal-title":"Alzheimers Dementia"},{"issue":"11","key":"8524_CR95","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"WM Pardridge","year":"2012","unstructured":"Pardridge, W. M. (2012). Drug transport across the blood-brain barrier. Journal of Cerebral Blood Flow & Metabolism, 32(11), 1959\u20131972. https:\/\/doi.org\/10.1038\/jcbfm.2012.126 .","journal-title":"Journal of Cerebral Blood Flow & Metabolism"},{"issue":"2","key":"8524_CR96","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1517\/17425247.2014.952627","volume":"12","author":"WM Pardridge","year":"2015","unstructured":"Pardridge, W. M. (2015). Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. Expert Opinion on Drug Delivery, 12(2), 207\u2013222. https:\/\/doi.org\/10.1517\/17425247.2014.952627 .","journal-title":"Expert Opinion on Drug Delivery"},{"issue":"7","key":"8524_CR97","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1517\/17425247.2016.1171315","volume":"13","author":"WM Pardridge","year":"2016","unstructured":"Pardridge, W. M. (2016). CSF, blood-brain barrier, and brain drug delivery. Expert Opinion on Drug Delivery, 13(7), 963\u2013975. https:\/\/doi.org\/10.1517\/17425247.2016.1171315 .","journal-title":"Expert Opinion on Drug Delivery"},{"issue":"6","key":"8524_CR98","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40259-017-0248-z","volume":"31","author":"WM Pardridge","year":"2017","unstructured":"Pardridge, W. M. (2017). Delivery of biologics across the blood-brain barrier with molecular Trojan horse technology. BioDrugs, 31(6), 503\u2013519. https:\/\/doi.org\/10.1007\/s40259-017-0248-z .","journal-title":"BioDrugs"},{"key":"8524_CR99","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00730","author":"WM Pardridge","year":"2018","unstructured":"Pardridge, W. M., Boado, R. J., Patrick, D. J., Ka-Wai Hui, E., & Lu, J. Z. (2018). Blood-brain barrier transport, plasma pharmacokinetics, and neuropathology following chronic treatment of the rhesus monkey with a brain penetrating humanized monoclonal antibody against the human transferrin receptor. Molecular Pharmaceutics. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00730 .","journal-title":"Molecular Pharmaceutics"},{"issue":"9","key":"8524_CR100","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/archneurol.2009.196","volume":"66","author":"F Portet","year":"2009","unstructured":"Portet, F., Scarmeas, N., Cosentino, S., Helzner, E. P., & Stern, Y. (2009). Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study. Archive of Neurology, 66(9), 1120\u20131126. https:\/\/doi.org\/10.1001\/archneurol.2009.196 .","journal-title":"Archive of Neurology"},{"issue":"189","key":"8524_CR101","doi-asserted-by":"publisher","first-page":"189ra177","DOI":"10.1126\/scitranslmed.3005615","volume":"5","author":"R Potter","year":"2013","unstructured":"Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., et al. (2013). Increased in vivo amyloid-beta42 production, exchange, and loss in presenilin mutation carriers. Science Translational Medicine, 5(189), 189ra177. https:\/\/doi.org\/10.1126\/scitranslmed.3005615 .","journal-title":"Science Translational Medicine"},{"key":"8524_CR102","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/bs.apha.2014.06.001","volume":"71","author":"JE Preston","year":"2014","unstructured":"Preston, J. E., Abbott, N. J., & Begley, D. J. (2014). Transcytosis of macromolecules at the blood-brain barrier. Advances in Pharmacology, 71, 147\u2013163. https:\/\/doi.org\/10.1016\/bs.apha.2014.06.001 .","journal-title":"Advances in Pharmacology"},{"issue":"27","key":"8524_CR103","doi-asserted-by":"publisher","first-page":"7212","DOI":"10.1523\/JNEUROSCI.1450-06.2006","volume":"26","author":"C Priller","year":"2006","unstructured":"Priller, C., Bauer, T., Mitteregger, G., Krebs, B., Kretzschmar, H. A., & Herms, J. (2006). Synapse formation and function is modulated by the amyloid precursor protein. Journal of Neuroscience, 26(27), 7212\u20137221. https:\/\/doi.org\/10.1523\/jneurosci.1450-06.2006 .","journal-title":"Journal of Neuroscience"},{"issue":"14","key":"8524_CR104","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S., & Mobius, H. J. (2003). Memantine in moderate-to-severe Alzheimer\u2019s disease. New England Journal of Medicine, 348(14), 1333\u20131341. https:\/\/doi.org\/10.1056\/NEJMoa013128 .","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"8524_CR105","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1503\/jpn.110190","volume":"38","author":"TJ Revett","year":"2013","unstructured":"Revett, T. J., Baker, G. B., Jhamandas, J., & Kar, S. (2013). Glutamate system, amyloid ss peptides and tau protein: Functional interrelationships and relevance to Alzheimer disease pathology. Journal of Psychiatry Neurosci, 38(1), 6\u201323. https:\/\/doi.org\/10.1503\/jpn.110190 .","journal-title":"Journal of Psychiatry Neurosci"},{"issue":"5","key":"8524_CR106","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/j.1476-5381.1995.tb13303.x","volume":"114","author":"GP Reynolds","year":"1995","unstructured":"Reynolds, G. P., Mason, S. L., Meldrum, A., De Keczer, S., Parnes, H., Eglen, R. M., et al. (1995). 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. British Journal of Pharmacology, 114(5), 993\u2013998.","journal-title":"British Journal of Pharmacology"},{"issue":"Pt 2","key":"8524_CR107","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1242\/jcs.104.2.521","volume":"104","author":"RL Roberts","year":"1993","unstructured":"Roberts, R. L., Fine, R. E., & Sandra, A. (1993). Receptor-mediated endocytosis of transferrin at the blood-brain barrier. Journal of Cell Science, 104(Pt 2), 521\u2013532.","journal-title":"Journal of Cell Science"},{"issue":"1","key":"8524_CR108","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/JAD-160500","volume":"55","author":"Y Rodriguez Cruz","year":"2017","unstructured":"Rodriguez Cruz, Y., Strehaiano, M., Obaya, R., Garcia Rodriguez, T., J. C., & Maurice, T. (2017). An intranasal formulation of erythropoietin (Neuro-EPO) prevents memory deficits and amyloid toxicity in the APPSwe transgenic mouse model of Alzheimer\u2019s disease. Journal of Alzheimers Disease, 55(1), 231\u2013248. https:\/\/doi.org\/10.3233\/jad-160500 .","journal-title":"Journal of Alzheimers Disease"},{"issue":"6543","key":"8524_CR109","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/376775a0","volume":"376","author":"EI Rogaev","year":"1995","unstructured":"Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., et al. (1995). Familial Alzheimer\u2019s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer\u2019s disease type 3 gene. Nature, 376(6543), 775\u2013778. https:\/\/doi.org\/10.1038\/376775a0 .","journal-title":"Nature"},{"issue":"5","key":"8524_CR110","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/0197-4580(96)00115-7","volume":"17","author":"J Rogers","year":"1996","unstructured":"Rogers, J., Webster, S., Lue, L. F., Brachova, L., Civin, W. H., Emmerling, M., et al. (1996). Inflammation and Alzheimer\u2019s disease pathogenesis. Neurobiology of Aging, 17(5), 681\u2013686.","journal-title":"Neurobiology of Aging"},{"issue":"8","key":"8524_CR111","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1073\/pnas.95.8.4635","volume":"95","author":"M Sakanaka","year":"1998","unstructured":"Sakanaka, M., Wen, T. C., Matsuda, S., Masuda, S., Morishita, E., Nagao, M., et al. (1998). In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A, 95(8), 4635\u20134640.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8524_CR112","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejphar.2015.11.046","volume":"770","author":"DM Samy","year":"2016","unstructured":"Samy, D. M., Ismail, C. A., Nassra, R. A., Zeitoun, T. M., & Nomair, A. M. (2016). Downstream modulation of extrinsic apoptotic pathway in streptozotocin-induced Alzheimer\u2019s dementia in rats: Erythropoietin versus curcumin. European Journal of Pharmacology, 770, 52\u201360. https:\/\/doi.org\/10.1016\/j.ejphar.2015.11.046 .","journal-title":"European Journal of Pharmacology"},{"issue":"6","key":"8524_CR113","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1212\/01.WNL.0000154529.53488.30","volume":"64","author":"M Sarazin","year":"2005","unstructured":"Sarazin, M., Stern, Y., Berr, C., Riba, A., Albert, M., Brandt, J., et al. (2005). Neuropsychological predictors of dependency in patients with Alzheimer disease. Neurology, 64(6), 1027\u20131031. https:\/\/doi.org\/10.1212\/01.wnl.0000154529.53488.30 .","journal-title":"Neurology"},{"issue":"4","key":"8524_CR114","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.beem.2010.06.001","volume":"24","author":"D Sargin","year":"2010","unstructured":"Sargin, D., Friedrichs, H., El-Kordi, A., & Ehrenreich, H. (2010). Erythropoietin as neuroprotective and neuroregenerative treatment strategy: Comprehensive overview of 12 years of preclinical and clinical research. Best Practice & Research: Clinical Anaesthesiology, 24(4), 573\u2013594. https:\/\/doi.org\/10.1016\/j.bpa.2010.10.005 .","journal-title":"Best Practice & Research: Clinical Anaesthesiology"},{"issue":"4","key":"8524_CR115","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1212\/WNL.50.4.991","volume":"50","author":"N Schupf","year":"1998","unstructured":"Schupf, N., Kapell, D., Nightingale, B., Rodriguez, A., Tycko, B., & Mayeux, R. (1998). Earlier onset of Alzheimer\u2019s disease in men with Down syndrome. Neurology, 50(4), 991\u2013995.","journal-title":"Neurology"},{"issue":"4","key":"8524_CR116","doi-asserted-by":"publisher","first-page":"270","DOI":"10.2174\/156720211798120990","volume":"8","author":"YC Shang","year":"2011","unstructured":"Shang, Y. C., Chong, Z. Z., Wang, S., & Maiese, K. (2011). Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia. Current Neurovascular Research, 8(4), 270\u2013285.","journal-title":"Current Neurovascular Research"},{"issue":"3","key":"8524_CR117","doi-asserted-by":"publisher","first-page":"187","DOI":"10.18632\/aging.100440","volume":"4","author":"YC Shang","year":"2012","unstructured":"Shang, Y. C., Chong, Z. Z., Wang, S., & Maiese, K. (2012). Prevention of beta-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K\/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY), 4(3), 187\u2013201. https:\/\/doi.org\/10.18632\/aging.100440 .","journal-title":"Aging (Albany NY)"},{"issue":"s1","key":"8524_CR118","doi-asserted-by":"publisher","first-page":"S555","DOI":"10.3233\/JAD-179937","volume":"64","author":"EM Sigurdsson","year":"2018","unstructured":"Sigurdsson, E. M. (2018). Tau Immunotherapies for Alzheimer\u2019s Disease and Related Tauopathies: Progress and Potential Pitfalls. Journal of Alzheimers Disease, 64(s1), S555\u2013Ss565. https:\/\/doi.org\/10.3233\/jad-179937 .","journal-title":"Journal of Alzheimers Disease"},{"issue":"7","key":"8524_CR119","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1073\/pnas.87.7.2452","volume":"87","author":"TA Slotkin","year":"1990","unstructured":"Slotkin, T. A., Seidler, F. J., Crain, B. J., Bell, J. M., Bissette, G., & Nemeroff, C. B. (1990). Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy. Proceedings of the National Academy of Sciences of the United States of America, 87(7), 2452\u20132455.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"8524_CR120","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.arcmed.2012.11.003","volume":"43","author":"AL Sosa-Ortiz","year":"2012","unstructured":"Sosa-Ortiz, A. L., Acosta-Castillo, I., & Prince, M. J. (2012). Epidemiology of dementias and Alzheimer\u2019s disease. Archives of Medical Research, 43(8), 600\u2013608. https:\/\/doi.org\/10.1016\/j.arcmed.2012.11.003 .","journal-title":"Archives of Medical Research"},{"issue":"12","key":"8524_CR121","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal, D. R., Rub, U., Orantes, M., & Braak, H. (2002). Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology, 58(12), 1791\u20131800.","journal-title":"Neurology"},{"key":"8524_CR122","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-0-387-30011-5_13","volume-title":"Erythropoietin and the nervous system: novel therapeutic options for neuroprotection","author":"L Torup","year":"2006","unstructured":"Torup, L., & Leist, M. (2006). Development of non-erythropoietic erythropoietin variants for neuroprotection. In A. H\u00f6ke (Ed.), Erythropoietin and the nervous system: novel therapeutic options for neuroprotection (pp.\u00a0211\u2013219). Boston: Springer."},{"issue":"24","key":"8524_CR123","doi-asserted-by":"publisher","first-page":"9205","DOI":"10.1523\/JNEUROSCI.0950-15.2015","volume":"35","author":"D Ulrich","year":"2015","unstructured":"Ulrich, D. (2015). Amyloid-beta Impairs synaptic inhibition via GABA(A) receptor endocytosis. Journal of Neuroscience, 35(24), 9205\u20139210. https:\/\/doi.org\/10.1523\/jneurosci.0950-15.2015 .","journal-title":"Journal of Neuroscience"},{"key":"8524_CR124","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2147\/NDT.S4048","volume":"5","author":"RJ van Marum","year":"2009","unstructured":"van Marum, R. J. (2009). Update on the use of memantine in Alzheimer\u2019s disease. Neuropsychiatric Disease and Treatment, 5, 237\u2013247.","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"6","key":"8524_CR125","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1084\/jem.20021067","volume":"198","author":"P Villa","year":"2003","unstructured":"Villa, P., Bigini, P., Mennini, T., Agnello, D., Laragione, T., Cagnotto, A., et al. (2003). Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. Journal of Experimental Medicine, 198(6), 971\u2013975. https:\/\/doi.org\/10.1084\/jem.20021067 .","journal-title":"Journal of Experimental Medicine"},{"issue":"2","key":"8524_CR126","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1471-4159.2005.03033.x","volume":"93","author":"B Viviani","year":"2005","unstructured":"Viviani, B., Bartesaghi, S., Corsini, E., Villa, P., Ghezzi, P., Garau, A., et al. (2005). Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor. Journal of Neurochemistry, 93(2), 412\u2013421. https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03033.x .","journal-title":"Journal of Neurochemistry"},{"issue":"4","key":"8524_CR127","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S1474-4422(17)30044-3","volume":"16","author":"KA Vossel","year":"2017","unstructured":"Vossel, K. A., Tartaglia, M. C., Nygaard, H. B., Zeman, A. Z., & Miller, B. L. (2017). Epileptic activity in Alzheimer\u2019s disease: Causes and clinical relevance. Lancet Neurology, 16(4), 311\u2013322. https:\/\/doi.org\/10.1016\/s1474-4422(17)30044-3 .","journal-title":"Lancet Neurology"},{"issue":"3","key":"8524_CR128","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1752-8062.2009.00121.x","volume":"2","author":"HI Wan","year":"2009","unstructured":"Wan, H. I., Jacobsen, J. S., Rutkowski, J. L., & Feuerstein, G. Z. (2009). Translational medicine lessons from flurizan\u2019s failure in Alzheimer\u2019s disease (AD) trial: Implication for future drug discovery and development for AD. Clinical and Translational Science, 2(3), 242\u2013247. https:\/\/doi.org\/10.1111\/j.1752-8062.2009.00121.x .","journal-title":"Clinical and Translational Science"},{"issue":"10","key":"8524_CR129","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3978\/j.issn.2305-5839.2015.03.49","volume":"3","author":"WY Wang","year":"2015","unstructured":"Wang, W. Y., Tan, M. S., Yu, J. T., & Tan, L. (2015). Role of pro-inflammatory cytokines released from microglia in Alzheimer\u2019s disease. Annals of Translational Medicine, 3(10), 136. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.03.49 .","journal-title":"Annals of Translational Medicine"},{"issue":"1","key":"8524_CR130","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.celrep.2017.12.019","volume":"22","author":"F Weber","year":"2018","unstructured":"Weber, F., Bohrmann, B., Niewoehner, J., Fischer, J. A. A., Rueger, P., Tiefenthaler, G., et al. (2018). Brain Shuttle antibody for Alzheimer\u2019s disease with attenuated peripheral effector function due to an inverted binding mode. Cell Reports, 22(1), 149\u2013162. https:\/\/doi.org\/10.1016\/j.celrep.2017.12.019 .","journal-title":"Cell Reports"},{"issue":"Suppl 9","key":"8524_CR131","first-page":"7","volume":"64","author":"GL Wenk","year":"2003","unstructured":"Wenk, G. L. (2003). Neuropathologic changes in Alzheimer\u2019s disease. Journal of Clinical Psychiatry, 64(Suppl 9), 7\u201310.","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"8524_CR132","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1111\/febs.12172","volume":"280","author":"SD Wenker","year":"2013","unstructured":"Wenker, S. D., Chamorro, M. E., Vittori, D. C., & Nesse, A. B. (2013). Protective action of erythropoietin on neuronal damage induced by activated microglia. FEBS J, 280(7), 1630\u20131642. https:\/\/doi.org\/10.1111\/febs.12172 .","journal-title":"FEBS J"},{"issue":"1","key":"8524_CR133","doi-asserted-by":"publisher","first-page":"9520","DOI":"10.1038\/s41598-017-10422-x","volume":"7","author":"NC Wildburger","year":"2017","unstructured":"Wildburger, N. C., Esparza, T. J., & LeDuc, R. D. (2017). Diversity of Amyloid-beta Proteoforms in the Alzheimer\u2019s Disease Brain. Scientific Reports, 7(1), 9520, https:\/\/doi.org\/10.1038\/s41598-017-10422-x .","journal-title":"Scientific Reports"},{"issue":"9","key":"8524_CR134","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nm1484","volume":"12","author":"T Wyss-Coray","year":"2006","unstructured":"Wyss-Coray, T. (2006). Inflammation in Alzheimer disease: Driving force, bystander or beneficial response? Nature Medicine, 12(9), 1005\u20131015. https:\/\/doi.org\/10.1038\/nm1484 .","journal-title":"Nature Medicine"},{"issue":"261","key":"8524_CR135","doi-asserted-by":"publisher","first-page":"261ra154","DOI":"10.1126\/scitranslmed.3009835","volume":"6","author":"YJ Yu","year":"2014","unstructured":"Yu, Y. J., Atwal, J. K., Zhang, Y., Tong, R. K., Wildsmith, K. R., Tan, C., et al. (2014). Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Science Translational Medicine, 6(261), 261ra154. https:\/\/doi.org\/10.1126\/scitranslmed.3009835 .","journal-title":"Science Translational Medicine"},{"issue":"84","key":"8524_CR136","doi-asserted-by":"publisher","first-page":"84ra44","DOI":"10.1126\/scitranslmed.3002230","volume":"3","author":"YJ Yu","year":"2011","unstructured":"Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., et al. (2011). Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Science Translational Medicine, 3(84), 84ra44. https:\/\/doi.org\/10.1126\/scitranslmed.3002230 .","journal-title":"Science Translational Medicine"},{"issue":"5","key":"8524_CR137","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1046\/j.1471-4159.2001.00222.x","volume":"76","author":"Y Zhang","year":"2001","unstructured":"Zhang, Y., & Pardridge, W. M. (2001). Rapid transferrin efflux from brain to blood across the blood-brain barrier. Journal of Neurochemistry, 76(5), 1597\u20131600.","journal-title":"Journal of Neurochemistry"},{"issue":"11","key":"8524_CR138","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/nm.3700","volume":"20","author":"Z Zhang","year":"2014","unstructured":"Zhang, Z., Song, M., Liu, X., Kang, S. S., Kwon, I. S., Duong, D. M., et al. (2014). Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer\u2019s disease. Nature Medicine, 20(11), 1254\u20131262. https:\/\/doi.org\/10.1038\/nm.3700 .","journal-title":"Nature Medicine"},{"issue":"6","key":"8524_CR139","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1021\/mp1001763","volume":"7","author":"QH Zhou","year":"2010","unstructured":"Zhou, Q. H., Boado, R. J., Lu, J. Z., Hui, E. K., & Pardridge, W. M. (2010). Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse. Molecular Pharmaceutics, 7(6), 2148\u20132155. https:\/\/doi.org\/10.1021\/mp1001763 .","journal-title":"Molecular Pharmaceutics"},{"key":"8524_CR140","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.brainres.2011.01.061","volume":"1382","author":"QH Zhou","year":"2011","unstructured":"Zhou, Q. H., Hui, E. K., Lu, J. Z., Boado, R. J., & Pardridge, W. M. (2011). Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson\u2019s disease in the mouse. Brain Research, 1382, 315\u2013320. https:\/\/doi.org\/10.1016\/j.brainres.2011.01.061 .","journal-title":"Brain Research"}],"container-title":["NeuroMolecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12017-019-08524-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12017-019-08524-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12017-019-08524-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T12:37:37Z","timestamp":1662813457000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12017-019-08524-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":140,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["8524"],"URL":"https:\/\/doi.org\/10.1007\/s12017-019-08524-y","relation":{},"ISSN":["1535-1084","1559-1174"],"issn-type":[{"value":"1535-1084","type":"print"},{"value":"1559-1174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,17]]},"assertion":[{"value":"21 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}